Complete PSTV Stock Valuation Analysis
Comprehensive intrinsic value analysis using 2 different methodologies
PSTV DCF Analysis
PSTV (Plus Therapeutics, Inc.) discounted cash flow analysis with multiple scenarios, growth assumptions, and terminal value calculations
Financial Projections
| Metrics | 2022 (Historical) | 2023 (Historical) | 2024 (Historical) | 2025 (Projected) | 2026 (Projected) | 2027 (Projected) | 2028 (Projected) | 2029 (Projected) |
|---|---|---|---|---|---|---|---|---|
| Revenue | $224.0K | $4.9M | $0 | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth % | - | 2093.3% | -100.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% |
| EBIT | $-19.7M | $-13.3M | $0 | $0 | $0 | $0 | $0 | $0 |
| EBIT Margin % | -8800.0% | -271.1% | 0.0% | 5.0% | 5.0% | 5.0% | 5.0% | 5.0% |
| Tax Rate % | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% | 25.0% |
| NOPAT | $-14.8M | $-10.0M | $0 | $0 | $0 | $0 | $0 | $0 |
| NOPAT Margin % | -6600.0% | -203.4% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% |
| Capex | $509.0K | $160.0K | $146.0K | $0 | $0 | $0 | $0 | $0 |
| Capex / Revenue % | 227.2% | 3.3% | Infinity% | 3.3% | 3.1% | 2.9% | 2.8% | 2.7% |
| Depreciation | $619.0K | $628.0K | $723.0K | $NaN | $NaN | $NaN | $NaN | $NaN |
| D&A / Revenue % | 276.3% | 12.8% | Infinity% | NaN% | NaN% | NaN% | NaN% | NaN% |
| Change in NWC | $-3.9M | $-10.9M | $-9.4M | $0 | $0 | $0 | $0 | $0 |
| NWC Change / Revenue % | -1736.2% | -221.0% | -Infinity% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Unlevered FCF | $-10.8M | $1.3M | $10.0M | $NaN | $NaN | $NaN | $NaN | $NaN |
| UFCF % Chg. | - | 112.4% | 647.1% | NaN% | NaN% | NaN% | NaN% | NaN% |
| FCF / Revenue % | -4814.7% | 27.2% | Infinity% | NaN% | NaN% | NaN% | NaN% | NaN% |
| Discount Factor | - | - | - | 0.938 | 0.879 | 0.825 | 0.773 | 0.725 |
| Present Value of FCF | - | - | - | $NaN | $NaN | $NaN | $NaN | $NaN |
| Sum of PV of UFCF | - | - | - | $NaN | $NaN | $NaN | $NaN | $NaN |
WACC Calculation
Weighted Average Cost of Capital used for discounting cash flows.
| WACC Calculation | Value |
|---|---|
| Cost of Debt | 6.8% |
| Tax Rate | 25.0% |
| After Tax Cost of Debt | 5.1% |
| Risk Free Rate | 4.26% |
| Market Risk Premium | 4.3% |
| Beta | 0.62 |
| Cost of Equity | 7.0% |
| Total Debt | $3.4M |
| Market Cap | $16.3M |
| Total Capital | $19.6M |
| Debt Weighting | 17.1% |
| Equity Weighting | 82.9% |
| WACC | 6.6% |
Terminal Value
Choose between perpetuity growth or exit multiple methods.
| Terminal Value Calculation | Value |
|---|---|
| Terminal Growth Rate | 2.5% |
| Final Year FCF | $NaN |
| Terminal Value | $NaN |
| PV of Terminal Value | $NaN |
| Cumulative PV of UFCF | $NaN |
| Net Debt | $3.3M |
| Equity Value | $NaN |
| Shares Outstanding | 7.7M |
| Implied Share Price | $NaN |
| Current Share Price | $0 |
| Implied Upside/(Downside) | NaN% |
Valuation Summary
$NaN
Implied Price
$0.32
Current Price
NaN%
Upside/Downside
6.6%
WACC
PSTV Peer Valuation Analysis
Relative valuation based on comparable company trading multiples
Peer Valuation Analysis
Fair Value Range Analysis
Based on median multiples from 5 peer companies in Healthcare
P/E Ratio
$0.00
-100.0%
Peer Median: 0.0x
EV/EBITDA
$0.00
-100.0%
Peer Median: 0.0x
P/S Ratio
$0.32
+0.0%
Peer Median: 5.5x
Interpretation: Each multiple provides a different perspective on fair value. Consider which multiple is most relevant for PSTV's business model and current situation.
Multiple Comparison
| Multiple | PSTV Current | Peer Median | Peer Average | Premium/Discount | Assessment |
|---|---|---|---|---|---|
| P/E Ratio | -0.1x | 0.0x | 0.0x | -Infinity% | Undervalued |
| EV/EBITDA | Infinityx | 0.0x | 0.0x | Infinity% | Overvalued |
| P/S Ratio | 5.5x | 5.5x | 4.5x | 0.0% | Fair Value |
Peer Companies
Click any company to view their valuation
| Company | Market Cap | P/E Ratio | EV/EBITDA | P/S Ratio |
|---|---|---|---|---|
| $0.01B | 0.0x | 0.0x | 3.6x | |
| $0.01B | 0.0x | 0.0x | 488.6x | |
| $0.19B | 0.0x | 0.0x | 0.0x | |
| $0.02B | 0.0x | 0.0x | 5.5x | |
| $0.00B | 0.0x | 0.0x | 0.0x |